Domain Mapping of Human PEX5 Reveals Functional and
Structural Similarities to Saccharomyces cerevisiae Pex18p
and Pex21p*
Gabriele
Dodt
§,
Daniel
Warren¶,
Elisabeth
Becker
,
Peter
Rehling
, and
Stephen J.
Gould¶
From the Institut für Physiologische Chemie,
Systembiochemie Ruhr-Universität, 44801 Bochum,
Germany, the ¶ Department of Biological Chemistry, The Johns
Hopkins University, School of Medicine, Baltimore, Maryland 21205, and
the
Institut für Biochemie und Molekularbiologie,
Albert-Ludwigs Universität Freiburg, 79104 Freiburg,
Germany
Received for publication, July 23, 2001, and in revised form, September 4, 2001
 |
ABSTRACT |
PEX5 functions as an import receptor for proteins
with the type-1 peroxisomal targeting signal (PTS1). Although PEX5 is
not involved in the import of PTS2-targeted proteins in yeast, it is
essential for PTS2 protein import in mammalian cells. Human cells
generate two isoforms of PEX5 through alternative splicing, PEX5S and
PEX5L, and PEX5L contains an additional insert 37 amino acids long.
Only one isoform, PEX5L, is involved in PTS2 protein import, and PEX5L
physically interacts with PEX7, the import receptor for PTS2-containing
proteins. In this report we map the regions of human PEX5L involved in
PTS2 protein import, PEX7 interaction, and targeting to peroxisomes.
These studies revealed that amino acids 1-230 of PEX5L are required
for PTS2 protein import, amino acids 191-222 are sufficient for PEX7
interaction, and amino acids 1-214 are sufficient for targeting to
peroxisomes. We also identified a 21-amino acid-long peptide motif of
PEX5L, amino acids 209-229, that overlaps the regions sufficient for
full PTS2 rescue activity and PEX7 interaction and is shared by
Saccharomyces cerevisiae Pex18p and Pex21p, two yeast
peroxins that act only in PTS2 protein import in yeast. A mutation in
PEX5 that changes a conserved serine of this motif abrogates PTS2
protein import in mammalian cells and reduces the interaction of PEX5L
and PEX7 in vitro. This peptide motif also lies within
regions of Pex18p and Pex21p that interact with yeast PEX7. Based on
these and other results, we propose that mammalian PEX5L may have
acquired some of the functions that yeast Pex18p and/or Pex21p perform
in PTS2 protein import. This hypothesis may explain the essential role
of PEX5L in PTS2 protein import in mammalian cells and its lack of
importance for PTS2 protein import in yeast.
 |
INTRODUCTION |
Peroxisomes are ubiquitous organelles of eukaryotic cells that
participate in a wide variety of metabolic functions (1, 2).
Peroxisomes lack nucleic acids, and peroxisomal proteins are encoded by
nuclear genes. Enzymes that are destined for the peroxisome lumen, or
matrix, are synthesized in the cytoplasm and imported
post-translationally (3). Two targeting signals direct proteins into
the peroxisome lumen (4). The type-1 peroxisomal targeting signal, or
PTS11, is found on the vast
majority of matrix enzymes and consists of just three amino acids at
the extreme C terminus of the enzyme (5). Although the canonical PTS1
is serine-lysine-leucine-COOH, many sequence variants of the PTS1 have
been described in mammalian cells (6-12) and even more in yeast (13,
14), protozoa (15-17), and plants (18). The type-2 peroxisomal
targeting signal, or PTS2, is found on only a small number of
peroxisomal enzymes and is located at or near the N terminus
of proteins (19, 20). The canonical PTS2 is
arginine-leucine-X5-histidine-leucine, though sequence variants of the PTS2 have also been described previously (21-23).
PEX5 serves as the import receptor for PTS1-containing proteins
(24-31). Each PEX5 monomer contains a single, high affinity PTS1-binding site in its C-terminal half (32), a region that contains
six tetratricopeptide repeats (TPRs). The crystal structure of human
PEX5 bound to the PTS1 reveals the critical role of the TPR repeats in
PTS1 binding and provides a molecular model that explains much of what
we know about PTS1 function in mammalian cells (32). Although there is
not yet a molecular model for the PEX7·PTS2 complex, PEX7 does
display high affinity and specificity for the PTS2 (33-35), and a
variety of studies supports the hypothesis that PEX7·PTS2 interaction
is the first step in PTS2 protein import (34-39). PEX5 and PEX7 are
predominantly cytoplasmic proteins that are thought to cycle between
the cytoplasm and peroxisome as they direct newly synthesized matrix
enzymes from the cytoplasm to peroxisomes (27, 30, 34-38, 40-42).
Numerous other PEX gene products are also required for
import of PTS1- and PTS2-containing proteins. These include docking
factors for PEX5 and/or PEX7 (PEX13, PEX14) (43-53), putative
translocation factors (PEX12, PEX10, PEX2, PEX8), and several peroxins
with less defined roles in peroxisomal matrix protein import (PEX1,
PEX4, PEX6, PEX15, PEX17, PEX22, PEX23) (for review, see Ref. 54).
The peroxisome biogenesis disorders (PBDs) are a group of lethal
neurological diseases caused by defects in peroxisomal matrix enzyme
import and peroxisome assembly (55). The PBDs can be caused by
mutations in any of at least 12 different human PEX genes,
including PEX5 and PEX7 (54, 56). Mutations in
PEX5 can cause Zellweger syndrome, neonatal
adrenoleukodystrophy, or infantile Refsum disease (8, 27). These three
diseases represent a phenotypic continuum and are characterized by a
loss or reduction of virtually all peroxisomal metabolic functions (56,
57). In contrast to the Zellweger spectrum of disease caused by
PEX5 mutations, mutations in PEX7 cause
rhizomelic chondrodysplasia punctata (36, 37, 39, 58, 59). Patients
with rhizomelic chondrodysplasia punctata are characterized by defects
in PTS2 protein import, normal PTS1 protein import, and a more
restricted set of metabolic and developmental abnormalities that
involve PTS2-targeted enzymes (55, 60).
Studies of human PEX genes and cells derived from PBD
patients have contributed significantly to our understanding of
peroxisome biogenesis (54, 56, 61). This is particularly true in regard to PEX5. Human cell studies were the first to show that PEX5 is a
predominantly cytoplasmic, partly peroxisomal protein (27) that cycles
between the cytoplasm and peroxisome (40, 42), and the crystal
structure of the human PEX5·PTS1 complex has provided a molecular
model of PTS1 recognition (32). In addition, human cell studies were
the first to show that mammalian PEX5 is required for PTS2 protein
import (27, 29, 62). The requirement for PEX5 in PTS2 protein import
represents a significant departure from the PTS2 protein import pathway
in yeast, in which PTS2 protein import occurs normally in the absence
of PEX5 (24, 25). Studies in human cells, Chinese hamster ovary cells,
and transgenic mice have also established that mammalian PEX5 is
expressed in at least two forms, PEX5L and PEX5S, which are generated
by alternative splicing of a single PEX5 gene (27, 63-65).
PEX5L contains an insert 37 amino acids long that is positioned between
amino acids 214 and 215 of PEX5S. PEX5L also differs from PEX5S in that
it can rescue PTS2 protein import in PEX5-deficient cells at
a high frequency (64, 65) and appears to interact with PEX7, the PTS2
receptor (66).
These and other results have led to the hypothesis that PEX5L plays an
essential role in PTS2 protein import and that this role involves
binding to PEX7 and facilitating PEX7 transport to peroxisomes (66).
However, many issues remain to be addressed regarding the role of PEX5L
in PTS2 protein import. In this report, we have identified sequences of
PEX5L that are necessary for PTS2 protein import, interaction with
PEX7, and transport to peroxisomes. We also identified a short peptide
motif shared by PEX5L and the Saccharomyces cerevisiae
peroxins Pex18p and Pex21p, which participate only in PTS2 protein
import. These and other results raise the possibility that PEX5L may
represent a functional and structural homolog of the yeast peroxins
Pex18p and Pex21p.
 |
EXPERIMENTAL PROCEDURES |
Cell Lines and Culturing Conditions
The human skin fibroblast cell lines were kindly provided by
A. B. Moser and H. W. Moser (Kennedy Krieger Institute,
Baltimore, MD). All cell lines were transformed with the large
T-antigen of SV40 virus as described previously (27). Cells were
cultured in Dulbecco's modified Eagle's medium supplemented with 10%
(v/v) fetal calf serum, 2 mM L-glutamine,
100,000 units/liter penicillin, and 100 mg/liter streptomycin at 9%
CO2. Wild-type cells have normal PTS1 and PTS2 protein
import. PBD005 cells are homozygous for a mutation in PEX5, R390ter,
and do not import detectable levels of PTS1 or PTS2 proteins (55).
PBD054 cells are homozygous for a mutation in PEX12, S320F, have
detectable PTS1 and PTS2 protein import, and import PEX5 into
peroxisomes (55). PBD061 cells lack peroxisome membranes, and are
homozygous for a mutation in PEX16, R176ter (55).
Transfections, Indirect Immunofluorescence Microscopy, and
Antibodies
Transfections of fibroblasts were performed by electroporation
using the protocol outlined by Chang et al. (67) or using LipofectAMINE (Life Technologies) according to the manufacture's suggestions. Two days after transfection the cells were processed for
indirect immunofluorescence microscopy as described in Slawecki et al. (68). Standard permeabilization was for 5 min with
1% Triton X-100, which permeabilizes both plasma and peroxisome
membranes. Differential permeabilization was for 5 min with 25 µg/ml
digitonin, which permeabilizes the plasma membrane but does not
permeabilize the peroxisome membrane. The micrographs were made using a
Zeiss Axiophot microscope and Kodak Ektachrome Elite 400 or TMAX 400 film.
Polyclonal sheep anti-human catalase antibodies were obtained from The
Binding Site. Polyclonal rabbit anti-GFP antibodies were purchased from
CLONTECH. The monoclonal anti-myc (9E10) antibodies (69) were prepared by ammonium sulfate precipitation (25-50%, w/v)
and diafiltration from serum-free cell culture supernatants. Cy3- and Cy2-conjugated secondary antibodies were obtained from Dianova. Other fluorescent antibodies were purchased from Jackson Immunochemicals. Antibodies against chloramphenicol acetyltransferase (CAT) were obtained from 5 Prime
3 Prime, Inc. (Boulder,
CO). Anti-PEX5 antibodies were generated in rabbits against a
recombinant His6-tagged version of PEX5L. The plasmid
encoding full-length PEX5L, an N-terminal hexahistidinyl
(His6) tag and a tobacco etch virus protease cleavage side
in a derivative of pET9d (Novagen) has been described before (70). This
plasmid was transformed into Escherichia coli BL21(DE3), and
recombinant PEX5L protein was purified under native conditions
according to Schliebs et al. (70).
Plasmids
Mammalian Expression Vectors--
The PEX5S (pGD100) (27),
PEX5L (64) (pGD106), and PTS2-CAT (19) expression vectors have been
described. The remaining PEX5 expression plasmids used in the
PTS1 and PTS2 protein import and targeting studies (see Figs. 1-3, and
7) are derivatives of pcDNA3 (Invitrogen). These constructs were
named based on the region of PEX5 encoded by a particular plasmid. The
PEX5 coding region in each of these constructs was cloned into the
HindIII and BamHI sites in pcDNA3 in-frame
with an 11-amino acid c-myc epitope tag (for the sequence of the tag,
see below) located between the BamHI and XbaI
sites. For example, PEX5L/1-335myc encodes amino acids 1-335 of the
long isoform of PEX5 whereas PEX5S/1-298myc encodes amino acids 1-298
of the short isoform of PEX5 both in front of the myc tag. The same
system of nomenclature applies to PEX5L/1-300myc and PEX5S/1-263myc,
PEX5L/1-264myc and PEX5S/1-227myc, PEX5L/48-639myc and
PEX5S/48-602myc, PEX5L/1-241myc, PEX5L/1-230myc, PEX5L/1-222myc,
PEX5L/1-214myc, PEX5L/1-157myc, and PEX5L/1-90myc.
N-mycPEX7 (pEB13.10), containing the c-myc epitope encoding
sequence upstream of the PEX7 coding region, and the multiple cloning
site between the EcoRI and XbaI sites of
pcDNA3 downstream of the PEX7 coding region (see PEX7pcDNA3
(37)), was cloned into the HindIII and
XbaI sites of pcDNA3.1Zeo. The start codon of PEX7 was
omitted. The sequence upstream of the second PEX7 codon reads as
follows: (5'-A AGC TTC ACC ATG GAG CAG AAG CTG ATC AGC GAG GAG
GAC CTG GGA TCC AGG TAC CTT CTG-3'). The nucleotides encoding the
myc tag are underlined. PEX7 in pEGFP was created by cloning an
Acc65I and ApaI fragment of pEB6.4 (PEX7 in
pM, see below) into the corresponding sites of pEGFP-C1
(CLONTECH).
Yeast Two-Hybrid System--
The full-length PEX5L
and PEX5S coding regions were excised from pGD106 and pGD100 with
NcoI (blunted) and BglII and cloned into the
SmaI and BglII sites of the activating domain
vector pPC86 (71). PEX5S/1-228 in pPC86 (pGD142) was generated from pJM165.1 that contained amino acids 1-298 of PEX5 in pcDNA3 by cleavage with NcoI (blunted) and XbaI and
subsequent cloning into the SmaI and SpeI site of
pPC86. The plasmid pJM165.1 was generated by PCR using primers DV1037
and P299ter with pGD100 as template (Table I). The PCR fragment was
cleaved with Sse8387I and XbaI and cloned into
the corresponding sites of pGD100. PEX5L/1-251 in pPC86 (pEB4.2) was
generated by PCR using the primer pair T7 and GD30 with pGD106 as
template. The fragment was cleaved with EcoNI and
NotI and cloned into the respective sites of pGD142. PEX5L/48-298 in pPC86 (pEB2.2) was made by PCR with primers GD31 and
P299ter using pGD106 as template. The fragment was cleaved with
SalI and XbaI and cloned into the SalI
and SpeI site of pPC86. PEX5L/139-298 and PEX5L/214-298 in
pPC86 were cloned in the same way, but the sense primers GD32 and GD33
were used in the PCR reactions.
The ScPEX7 DNA in pPC97 was described by Rehling et al. (34).
Mammalian Two-Hybrid System--
HsPEX7
in pM (pEB6.4) was generated from pEB6.6 by excision of the
full-length DNA with EcoRI and cloning it into the
EcoRI site of pM. Plasmid pEB6.6 was generated by amplifying
a fragment with primers GD47 and Sp6 using PEX7pcDNA3 (37) as
template. This fragment was then subcloned into pGEM-T (Promega)
following the manufacturer's instructions. HsPEX7 in pVP16
was cloned in a similar way generating pEB6.5. To generate PEX5L and
PEX5S in pVP16 (pEB7.5 and pEB8.5), corresponding fragments were
cleaved with NcoI (blunted) and BglII from pGD106
or pGD100, and cloned into the EcoRI site (blunted) and
BamHI site of pVP16. HsPEX5L/1-335 in pVP16 was
generated by cleaving pJM164.7 with NcoI (blunted) and
XbaI and ligating the fragment into the EcoRI
(blunted) and XbaI sites of pVP16. The short version
HsPEX5S/1-298 in pVP16 (pEB 10.5) was derived in a similar
way from pJM165.1 that encoded amino acids 1-298 in pcDNA3.
HsPEX5L/1-251 in pVP16 (pEB4.5) was created by cleaving the
NcoI (blunted)/XbaI fragment out of pEB4.1 and
ligating it into the EcoRI (blunted) and XbaI
sites of pVP16. Plasmid pEB4.1 encodes PEX5L/1-251 in pcDNA3 and
was derived by PCR with the primer pair GD30 and T7 using pGD106 as
template. An EcoNI/NotI fragment was then ligated
into the corresponding sites of pGD100 to generate pEB4.1.
HsPEX5L/48-335 in pVP16 (pCK7) was generated by excising an
NcoI (blunted)/XbaI fragment from pEB2.1 and
cloning this fragment into the EcoRI (blunted) and XbaI sites of pVP16. To generate pEB2.1
(HsPEX5L/48-335pcDNA3) a fragment was amplified by PCR
with primers GD31 and P299ter using pGD106 as template. This fragment
was cut with SalI and XbaI and cloned into the
XhoI and XbaI sites of pcDNA3. The coding region of PEX5L/138-335 was amplified from pGD106 using primers GD32
and P299ter. The fragment was cleaved with SalI and
XbaI and ligated into the XhoI and
XbaI sites of pcDNA3. This plasmid was cut with
NcoI (blunted) and XbaI and cloned into the
EcoRI (blunted) and XbaI sites of pVP16 to
generate HsPEX5L/138-335 in pVP16 (pEB3.5). The
PEX5L/214-335 encoding fragment in pVP16 (pEB1.5) was cloned in a
similar way using primers GD33 and P299ter. To create
HsPEX5L/191-251 in pM (pEB16.4) the plasmid pEB4.1 encoding PEX5L/1-251 in pcDNA3 was cut Bsu36I (blunted) and
XbaI and cloned into the SmaI and XbaI
sites of pM. The latter vector was cleaved with EcoRI and
XbaI, and the similar fragment was ligated into the
corresponding sites of pVP16 (pEB16.5). The coding region for
HsPEX5L/191-222 was cleaved with BspMI (blunted)
and SacI out of pEB16.5 and ligated into pVP16
(HindIII (blunted) and SacI) to give
HsPEX5L/191-222 in pVP16 (pEB17.5). The sequence coding for
HsPEX5/1-131 was amplified with the T7 primer and primer
Ku582 using pGD100 as template. This fragment was cut with
NcoI (blunted) and SalI and cloned into the
EcoRI (blunted) and SalI sites of pVP16 to give
HsPEX5/1-131pVP16. ScPEX21 in pPC86 was provided by W. Schliebs (Bochum). The coding region was cleaved with
SalI (blunted) and XbaI and ligated into the
SalI (blunted) and SpeI sites of pM and pVP16,
respectively, to get ScPex21pM and ScPex21pVP16. HsPEX13 was cloned by reverse transcription-PCR (72)
using GD144 and GD145 as PCR primers, and mRNA isolated from
wild-type fibroblasts as template (Oligotex Direct mRNA kit,
Qiagen). A BamHI/XbaI fragment was cloned into
the corresponding sites of pVP16 and pM to give HsPEX13pVP16
and HsPEX13pM. The PEX13SH3 plasmids encode amino acids
257-447 of PEX13 in pVP16 and pM. A BamHI/XbaI
fragment was generated by PCR using the primer pair Ku341/Ku342. A
plasmid containing this fragment in pSK was kindly provided by G. Will (Bochum). The PEX14 plasmid in pVP16 has been described previously (52).
Immunoprecipitations
Transcription/Translation--
PEX5S (pGD100), PEX5L (pGD106),
and N-mycPEX7 (pEB13.10) were transcribed and translated in
vitro for 1 h, using the TNT Coupled Reticulocyte Lysate
system (Promega). PEX5 and PEX7 were labeled with
[35S]cysteine (1075 Ci/mmol) (PerkinElmer Life Sciences).
Equal amounts of the PEX5L, PEX5S, and N-mycPEX7 translation reactions
(10 µl) were mixed and incubated together for an additional hour at
30 °C. The reaction mixture was diluted to 175 µl with binding
buffer (20 mM Hepes, pH 7.3, 110 mM potassium
acetate, 5 mM sodium acetate, 2 mM magnesium
acetate, 1 mM EDTA, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride, 21 µg/ml NaF) containing 0.3% Triton X-100 and incubated for 2 additional hours at 4 °C with 25 µl of anti-mouse IgG
Dynabeads (Dynal), saturated with anti-myc antibodies.
Immunoprecipitates were collected using a magnet. The precipitates were
washed five times with 1 ml of binding buffer with 0.3% Triton X-100,
0.005% SDS, resuspended in 20 µl of SDS sample buffer, denatured for
5 min at 95 °C, and separated by SDS-PAGE. Supernatant and pellet
fractions were loaded with a ratio of 12.5 to 1. The gel was soaked in
0.5 M sodium salicylate for 30 min, dried, and subjected to fluorography.
Cell Lysates--
PBD005 cells in 60-mm dishes were transfected
with PEX5S-, PEX5L-, and N-mycPEX7-expressing plasmids using
LipofectAMINE as described. Two days later cells were washed with
Hanks' solution and lysed in 0.8 ml of binding buffer (see above)
supplemented with 0.5% Triton X-100 on ice for 30 min. The lysates
were cleared at 15,000 × g for 15 min. Supernatants
(600 µl) were incubated with 50 µl of anti-myc-coated mouse IgG
Dynabeads (Dynal) for 2 h. Immunoprecipitates were washed with
binding buffer with 0.5% Triton and 0.02% SDS as described above,
resuspended in 36 µl of non-reducing SDS sample buffer, denatured for
5 min at 95 °C, and separated from the beads. For analysis, samples
were supplemented with 1 µl of
-mercaptoethanol, denatured again
for 5 min at 95 °C, and separated by SDS-PAGE. The ratios for the
supernatant and pellet fractions loaded onto the gel were 20 to 1. The
proteins were transferred to a PVDF membrane and detected with
anti-PEX5 antibodies using the ECL system (Amersham Pharmacia
Biotech).
Mammalian Two-hybrid Methodology and ELISA
To investigate a possible interaction between human peroxins we
used the mammalian MATCHMAKER two-hybrid assay kit
(CLONTECH). The corresponding cDNAs were cloned
behind the GAL4 binding domain sequence of the pM vector or the
VP16-activating domain sequence of the pVP16 vector, as described under
"Plasmids." Human wild-type skin fibroblasts (GM5756) or
PEX16-deficient fibroblasts (PBD061) were seeded onto 12-well plates to
reach 50-80% confluency the next day. The cells were co-transfected
with 0.24 µg of DNA of pM and pVP16 derivatives together with 0.05 µg of reporter plasmid pG5CAT, using 1.5 µl of LipofectAMINE. Two
days after transfection, the cells were lysed in 0.2 ml of lysis buffer
(CAT ELISA kit (Roche Molecular Biochemicals)) for 30 min at
4 °C, and the supernatants were cleared at 15,000 × g for 15 min. The amount of proteins in cell lysates was
estimated using the BCA protein assay reagent (Pierce) and serum
albumin as standard. Lysates corresponding to 50 µg of protein were
used to determine the amount of chloramphenicol acetyltransferase with
the CAT ELISA kit. Similar transfected samples were controlled for
expression of the fusion proteins and for CAT expression by
immunofluorescence microscopy, using polyclonal antibodies against the
GAL4 binding domain (Santa Cruz Biotechnology) and against
chloramphenicol acetyltransferase (5 Prime
3 Prime, Inc.).
Yeast Two-hybrid System
The cDNAs were fused to the activation domain of GAL4 in
pPC86 or the GAL4 binding domain in pPC97 (71) as described above. Co-transformations of two-hybrid vectors into strain HF7c
(CLONTECH) or PCY2 (71) and PCY2
pex14
(73) were performed with lithium acetate following a protocol from
CLONTECH (Yeast Protocols Handbook). The
-galactosidase filter assay and the test for HIS
prototrophy were performed after selection on SD plates lacking
leucine and tryptophan according to Rehling et al. (34).
 |
RESULTS |
Identification of the Minimal PTS2 Import Domain of
PEX5L--
PBD005 cells were derived from a severely affected
Zellweger patient and are homozygous for a nonsense mutation in
PEX5, R390ter (27). This mutation results in the
destabilization of PEX5 mRNAs, the absence of detectable
PEX5 protein, and eliminates import of both PTS1- and PTS2-containing
proteins (27, 64). Additional studies have established that mammalian
cells express two forms of PEX5 that differ by 37 amino acids and that
these forms are generated by alternative splicing of a single exon of
the PEX5 gene (27, 64, 65). These forms appear to differ in
their biological activities, with PEXL efficiently rescuing both PTS1 and PTS2 protein import and PEX5S involved only in PTS1 protein import.
This difference can be detected using the following in vivo
assay. Plasmids designed to express (a) PTS2-CAT, a plasmid designed to express bacterial chloramphenicol acetyltransferase (CAT)
with a PTS2 at its N terminus (19) and (b) either PEX5S or
PEX5L (64), were simultaneously introduced into PBD005 cells by
electroporation. Two days after transfection, the cells were processed
for indirect immunofluorescence microscopy (Fig.
1). The relative ability of PEX5S and
PEX5L to mediate PTS2 protein import was calculated by comparing the
percentage of cells in which PTS1 protein import was detected to the
percentage of cells in which PTS2 protein (PTS2-CAT) import was
detected. For PEX5L, the values were equivalent whereas PEX5S was 100 times less efficient at rescuing PTS2 protein import than it was at
rescuing PTS1 protein import.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 1.
The long form of PEX5 rescues PTS2 import 100 times more efficiently than PEX5S. PBD005 cells were
co-transfected with plasmids encoding either PEX5L (a,
d) or PEX5S (b, c, e,
f) and PTS2-CAT. After 2 days the cells were processed for
double-indirect immunofluorescence microscopy with anti-CAT
(a-c) and anti-PMP70 (d-f). Cells transfected
with plasmids for PEX5S displayed cytoplasmic distribution of PTS2-CAT
antibodies (b) 100 times more frequently than the
peroxisomal distribution shown in c.
|
|
To better understand the molecular basis of PEX5-mediated PTS2 protein
import, we mapped the minimal PTS2-import domain of PEX5L using the
immunofluorescence-based in vivo assay described above. The
C-terminal half of PEX5 is involved in binding the PTS1, and we
hypothesized that it might be dispensable for PTS2 protein import. We
removed this domain by cloning the upstream codons of PEX5S (1)
and PEX5L (1) into a mammalian expression vector that is designed
to add a c-myc epitope tag to the C terminus of each gene product. The
resulting clones (PEX5S/1-298myc and PEX5L/1-335myc) contained 12 codons encoding a c-myc epitope tag (GSQNLISQQDL-stop) in place of the last 304 codons
of PEX5S and PEX5L. PEX5S/1-298myc and PEX5L/1-335myc were then
tested for their ability to rescue PTS1 and PTS2 protein import in
PBD005 cells (Fig. 2). These proteins
were unable to rescue PTS1 protein import, and PEX5S/1-298myc was
unable to rescue PTS2 protein import. However, expression of
PEX5L/1-335myc rescued PTS2 protein import with nearly the same
efficiency as full-length PEX5L. We generated additional C-terminal
truncation mutants of PEX5S and PEX5L that removed their C-terminal 339 amino acids (PEX5S/1-263myc and PEX5L/1-300myc) or their C-terminal
375 amino acids (PEX5S/1-227myc and PEX5L/1-264myc). Neither of these
proteins was capable of rescuing PTS1 protein import, but the "L"
versions were capable of rescuing PTS2 protein import. Removal of the
N-terminal 48 amino acids of PEX5S and PEX5L eliminated the ability of
the proteins to rescue PTS1 and PTS2 protein import.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 2.
The N-terminal but not the C-terminal region
of PEX5L is required for PTS2 import. PBD005 cells were
co-transfected with the constructs expressing the various PEX5 proteins
shown in e and with the plasmid expressing PTS2-CAT. After 2 days the cells were processed for double-indirect immunofluorescence
microscopy with anti-CAT antibodies (a, c) and
anti-PMP70 antibodies (b, d). PEX5S/1-227myc
(a, b) did not rescue PTS2 import (a)
whereas the long isoform of that protein, PEX5L/1-264myc
(c, d), does restore PTS2 import (c).
White boxes represent the six TPR domains involved in PTS1
binding. The amino acids encoded by the alternative exon
(AE) are indicated by the gray box.
|
|
PEX5L/1-264myc contained all sequences upstream of the 37-amino acid
insert, the entire insert, plus the 13 amino acids C-terminal to the
37-amino acid insert. We created four more mutants of PEX5L that
removed an additional 23 (PEX5L/1-241myc), 34 (PEX5L/1-230myc), 42 (PEX5L/1-222myc), and 50 (PEX5/1-214myc) amino acids from the C
terminus of PEX5L/1-264myc (Fig. 3).
PEX5L/1-241myc and PEX5L/1-230myc lacked the C-terminal 10 and 21 amino acids of the 37-amino acid insert, respectively, but still
rescued PTS2 protein import with high efficiency. The next smallest
mutant that removed the C-terminal 29 amino acids of the 37-amino acid
insert (PEX5L/1-222myc) displayed only a borderline ability to rescue
PTS2 protein import. Loss of the entire insert (PEX5/1-214myc)
eliminated the ability of PEX5 to rescue PTS2 protein import in PBD005
cells. Thus, we find that the C-terminal 21 amino acids of the insert
can be removed from PEX5L without eliminating its ability to rescue
PTS2 protein import.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 3.
The C-terminal 21 amino acids of the 37-amino
acid insert can be removed from PEX5L without eliminating PTS2
import. PBD005 cells were co-transfected with the plasmids
encoding the PEX5 proteins listed and PTS2-CAT. After 2 days the cells
were processed for double-indirect immunofluorescence microscopy with
anti-CAT antibodies and anti-PMP70 antibodies. The level of PTS2 rescue
associated with each construct is indicated. (+) indicates that
PEX5L/1-222myc showed only borderline rescue activity. The
underlined sequence indicates the amino acids encoded by the
alternative exon of PEX5L.
|
|
Identification of a PEX7 Binding Domain within PEX5L--
In
a previous study, Fujiki and colleagues reported that PEX5L can bind
PEX7 whereas PEX5S cannot (66). To map the site of interaction between
PEX5L and PEX7 we first examined our ability to detect this interaction
in vivo. PBD005 cells were transfected with plasmids
designed to express N-mycPEX7 (a fully functional form of the protein
(37)), PEX5S, PEX5L, or co-transfected with combinations of the PEX7
and PEX5 expression vectors. Two days after transfection, lysates were
prepared from each transfected cell population and subjected to
immunoprecipitation using anti-myc antibody beads. The resulting
immunoprecipitates (IPs) were then separated by SDS-PAGE, transferred
to a PVDF membrane, and probed with antibodies specific for PEX5 (Fig.
4a). PBD005 cells do not express any PEX5 proteins, and PEX5 proteins were not detected in the
IP from cells expressing only N-mycPEX7. IPs from cells expressing
either PEX5S or PEX5L contained a low level of PEX5, which represents
our background of PEX5 binding to anti-mouse IgG Dynabeads. Relative to
this background, the amount of PEX5S in the IP from cells expressing
PEX5S and N-mycPEX7 was negligible. In contrast, the amount of PEX5L
detected in the IP from cells expressing N-mycPEX7 and PEX5L was
significantly higher than background.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 4.
a, PEX5L can be co-immunoprecipitated
with N-myc-PEX7 from transfected fibroblasts. PEX5-deficient cells were
transfected with plasmids encoding PEX5S or PEX5L and myc-PEX7. After 2 days the cells were lysed in 0.5% Triton X-100. Anti-myc antibodies
coated to Dynabeads were used to precipitate mycPEX7. The
precipitate was separated by SDS-PAGE, blotted to a PVDF membrane, and
probed with anti-PEX5 antibodies. The supernatants were given as a
control for expression of the different PEX5 proteins. The ratio
between pellet and supernatant loaded onto the gel was 20 to 1. b, immunoprecipitation of in vitro transcribed
and translated proteins. PEX5L, PEX5S, and mycPEX7 were separately
transcribed and translated in vitro with
[35S]cysteine. Equal amounts of the same protein pairs as
given in a were incubated together for one additional hour
and then precipitated with anti-myc-coated Dynabeads. Pellet and
supernatant fractions were separated on 10% SDS gels. The ratio
between pellet fraction and supernatant was 12.5 to 1. The gels were
dried and subjected to fluorography. The positions of the labeled
proteins are indicated on the right. No significant amounts
of PEX5S or PEX5L could be detected in the precipitates.
|
|
The signal for PEX5L·PEX7 interaction detected above was not
particularly robust and led us to doubt whether we could use this assay
to map the region of PEX5L that mediates its interaction with PEX7. We
next tested whether we could detect this interaction in a slightly more
defined system using radiolabeled proteins. Specifically, we
synthesized N-mycPEX7, PEX5S, and PEX5L in the presence of
[35S]cysteine in rabbit reticulocyte lysates for 1 h, mixed equal amounts of the respective pairs, incubated them for an
additional hour at 30 °C, and then subjected each sample to
immunoprecipitation with anti-myc antibodies. We were unable to detect
interaction between PEX5L and PEX7 in this system (Fig. 4b).
We also tried to assess binding between PEX5L and PEX7 using purified
recombinant proteins expressed in bacteria in a variety of blot
overlay, bead binding, and other protein·protein association
assays. These experiments also failed to show an interaction
between PEX5L and PEX7. These protein·protein interaction
assays rely on a number of assumptions regarding the relative affinity
of the binding reaction, the conformational constraints of the
interaction, the conformational status of the bacterially expressed
proteins, and the ability of the interaction to occur in the absence of
other factors. Thus, these results should not be interpreted
as evidence against direct PEX5L·PEX7 binding. They did
force us, however, to search for another assay system in which we
could examine the PEX5L·PEX7 interaction.
The mammalian two-hybrid protein interaction assay makes fewer
assumptions regarding the variables described above, and we therefore
tested whether it could be used to map the region of PEX5L that
interacts with PEX7. The mammalian two-hybrid system (74) operates on
the same principle as the yeast two-hybrid system but offers certain
advantages. These include the ability to more easily control for
expression and localization of test proteins, adaptability to a wide
range of cell lines, and the ability to assay reporter gene expression
on a cell-by-cell basis as well as on an averaged basis for the entire
cell population. The particular assay system we employed uses the
cDNA for chloramphenicol acetyltransferase (CAT) as the reporter,
which is under the control of a GAL4-responsive promoter. Test proteins
are expressed as fusions to either the GAL4 DNA binding domain (BD) or
the transcriptional transactivation domain of VP16 (AD). Cells are then
co-transfected with all three plasmids, and the interaction is scored
by the extent of CAT expression in lysates prepared from transfected cells, which can be determined by ELISA as well as by indirect immunofluorescence microscopy (IIF).
Isolated expression of BD-PEX7, AD-PEX5S, and AD-PEX5L fusion proteins
had no effect on GAL4-mediated expression of CAT in this assay (Table
II). Co-expression of BD-PEX7 and
AD-PEX5S also failed to activate the CAT reporter gene, but
simultaneous expression of BD-PEX7 and AD-PEX5L led to
significant expression of CAT protein, as determined by ELISA of
cell lysates (Table II) and by IIF microscopy (Fig.
5). The equal expression of PEX5S and
PEX5L was controlled by IIF microscopy using antibodies against PEX5 or
the activating domain. This experiment was also performed in
PEX16-deficient PBD061 cells, which lack peroxisome
membranes, to determine whether the interaction was dependent upon the
presence of peroxisome membranes or a functional peroxisomal import
apparatus (75, 76). The PEX7·PEX5L interaction was even stronger in
these peroxisome-deficient cells, as determined by ELISA (Table II) and
IIF microscopy (data not shown).

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 5.
HsPEX7 only interacts with the long form of
HsPEX5 in a mammalian two-hybrid assay. Wild-type
fibroblasts were co-transformed with plasmids encoding fusions of PEX5L
(a) or PEX5S (b) with the VP16 activation domain
(AD), fusions of PEX7 with the GAL4 binding domain (BD), and with a
reporter plasmid encoding GAL4-dependent CAT. Activation of
the expression of CAT was investigated by immunofluorescence microscopy
using polyclonal antibodies against CAT (a, b).
Only the co-expression of plasmids encoding AD-PEX5L and BD-PEX7
resulted in a cytosolic expression of CAT (a) whereas no CAT
expression was found with AD-PEX5S and BD-PEX7 (b). The
expression of the PEX7 binding domain plasmid in both
co-transfections with AD-PEX5L (c) or AD-PEX5S
(d) was controlled with anti-binding domain antibodies, and
the equal expression rates of AD-PEX5S and AD-PEX5L were monitored with
anti-PEX5 antibodies (data not shown).
|
|
We next assayed the interaction between PEX7 and various deletion
mutants of PEX5S and PEX5L (Table II). PEX7 interacted with fragments
containing amino acids 1-335, 1-251, 48-335, 139-335, 191-251, and
191-222 of PEX5L. These results suggest that amino acids 191-222 of
PEX5L are sufficient for interaction with PEX7 and that the
interaction isincreased with a slightly longer fragment of PEX5L
(PEX5L/191-251).
Negative results in this assay are more difficult to interpret. Loss of
interaction may reflect an interesting phenomenon, such as elimination
or disruption of a protein·protein interaction motif, but negative
results can also be caused by other factors, including reduced
expression, aberrant folding, and altered subcellular distribution. In
these experiments, we were able to control for expression and
subcellular distribution of the various AD-PEX5L fusions, which were
equivalent, but controls for folding were obviously beyond the limits
of our experimental approach. Nevertheless, the lack of interaction
between PEX7 and fragments of PEX5 that do not contain the 37-amino
acid insert of PEX5L is consistent with the hypothesis that all or part
of this insert plays an important role in PEX7 interaction. In
addition, the lack of interaction between PEX7 and PEX5L/214-335
raises the possibility that some or all of the 14 amino acids upstream
of the 37-amino acid insert in PEX5L are also involved in the
interaction with PEX7.
The hypothesis that the PEX7 interaction domain of PEX5L is important
for PTS2 protein import predicts that expression of this domain alone
should inhibit PTS2 protein import. To test this hypothesis we
co-transfected normal human fibroblasts with the PTS2-CAT expression
vector and with either pM or pM-PEX5L/191-251. Two days after
transfection the cells were processed for IIF microscopy. The
percentage of cells in each population that showed import of PTS2-CAT
into peroxisomes was determined by assessing PTS-CAT distribution in
hundreds of transfected cells. In cells co-transfected with pM,
PTS2-CAT was peroxisomal in 85% of expressing cells whereas it was
peroxisomal in only 22% of cells co-transfected with
pM-PEX5L/191-251. Thus, overexpression of PEX5L/191-251 in normal
human fibroblasts inhibited PTS2 protein import by ~75%.
Could PEX5L Represent a Functional Homolog of Yeast
Pex18p/Pex21p?--
Like PEX5L in mammalian cells, S. cerevisiae Pex18p and Pex21p interact with S. cerevisiae Pex7 and are required for PTS2 protein import (77). We
therefore tested whether mammalian PEX5 shared any other properties
with yeast Pex18p and Pex21p. These yeast peroxins have an important
role in targeting S. cerevisiae Pex7p to peroxisomes (77),
and we therefore investigated whether PEX5 was required for PEX7
targeting in human cells. Although yeast Pex7p has been described as a
predominantly cytoplasmic, partly peroxisomal protein (34, 35, 38),
certain tagged versions of Pex7p will actually accumulate within
peroxisomes (33). A fusion protein between enhanced green fluorescence
protein (EGFP) and human PEX7 (EGFP-PEX7) displays this property, as
shown by its peroxisomal distribution in normal human fibroblasts (Fig. 6, a and b) that
was not detectable when the cells were differentially permeabilized
with digitonin indicating an intraperoxisomal localization (Fig. 6,
c and d). We expressed the same EGFP-PEX7 fusion
protein in PEX5-deficient PBD005 cells and found that it
remained completely in the cytoplasm (Fig. 6, e and
f), even though these cells contain numerous peroxisomes
(27, 68, 78).

View larger version (134K):
[in this window]
[in a new window]
|
Fig. 6.
EGFP-PEX7 has a peroxisomal localization in
wild-type fibroblasts but is not targeted to peroxisomes in
PEX5-deficient PBD005 cells. EGFP-PEX7 was expressed in wild-type
fibroblasts (a-d) or in PEX5-deficient PBD005 cells
(e, f). Permeabilization was either done with
Triton X-100 (a, b, e, f)
or with digitonin (c, d), which did not
permeabilize the peroxisome membrane. a, EGFP-PEX7 shows a
cytoplasmic and peroxisomal distribution in wild-type cells visualized
with antibodies against EGFP. b, the same cells stained for
peroxisomal catalase. c and d, digitonin
permeabilization reveals a peroxisomal and cytoplasmic localization of
EGFP-PEX7 when the intrinsic fluorescence of EGFP, which is independent
of permeabilization, is monitored (c). No peroxisomal
staining is noticeable when antibodies against EGFP were used
(d). This indicates that most of the peroxisomal EGFP
staining accounts for intraperoxisomal EGFP-PEX7 molecules.
e and f, EGFP-PEX7 has an exclusively
cytoplasmic localization in PEX5-deficient PBD005 cells, when
stained with antibodies against EGFP (e). The identical cell
stained with antibodies against catalase, indicating the PTS1 import
defect of these cells that leads to a cytoplasmic localization of
catalase (f).
|
|
The hypothesis that PEX5L mediates the transport of PEX7 to
peroxisomes predicts that the minimal PTS2 rescue domain of PEX5L contains at least two functional elements: one that is sufficient for
interaction with PEX7 and another that is sufficient for targeting to
peroxisomes. It is not a trivial issue to assay the targeting of PEX5
proteins to peroxisomes, because PEX5 is a predominantly cytoplasmic,
partly peroxisomal protein (27). For example ~95% of the total PEX5
protein is located in the cytoplasm of normal human fibroblasts.
However, certain PBD cells with mutations in other PEX genes
trap PEX5 on or in peroxisomes (40, 79), and we took advantage of this
phenotype to determine whether the minimal PTS2 import domain of PEX5L
was sufficient for peroxisomal targeting. PBD054 cells are homozygous
for a missense mutation (S320F) in PEX12 and accumulate PEX5 on or in
the peroxisome (79). We transfected PBD054 cells with plasmids designed
to express various myc-tagged PEX5 proteins. Two days after
transfection the subcellular distribution of these proteins was
assessed by immunofluorescence microscopy using anti-myc antibodies
(Fig. 7). PEX5/1-214 was the smallest fragment that retained peroxisomal targeting, and this region is
contained within the smallest fragment of PEX5L that is sufficient for
PTS2 protein import (PEX5L/1-230myc). Smaller fragments of PEX5 (amino
acids 1-157 and 1-90) failed to target to peroxisomes and were
instead located only in the cytoplasm.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 7.
The N-terminal 214 amino acids are sufficient
to target PEX5 to peroxisomes. PBD054 cells have a defect in PEX12
and accumulate PEX5 at or in the peroxisomes. These cells were
transfected with plasmids designed to express the various myc-tagged
PEX5 proteins given in c. The PEX5 distribution was
monitored by immunofluorescence microscopy with anti-myc antibodies and
anti-PMP70 antibodies. The immunofluorescence microscopy revealed a
peroxisomal accumulation of PEX5/1-214myc (a), indicated by
its colocalization with the peroxisomal membrane protein PMP70
(b). White boxes represent the six TPR domains
involved in PTS1 binding. The gray box indicates the amino
acids encoded by the alternative exon (AE).
|
|
PEX5L shares three properties with the S. cerevisiae
peroxins Pex18p and Pex21p. All three proteins interact with PEX7, play an important role in PTS2 protein import, and play an important role in
directing PEX7 to peroxisomes. These common properties led us to
examine PEX5L, ScPex18p, and ScPex21p for any
shared sequence motifs, and we identified a 21-amino acid-long peptide motif in all three proteins (Fig. 8).
This motif (amino acids 209-229) is located within the minimal PTS2
rescue domain of PEX5L (amino acids 1-230), and a PEX5L fragment that
lacked the C-terminal 7 amino acids of this element (PEX5L/1-222)
displayed only a borderline ability to rescue PTS2 protein import. Most
of this motif also matches the smallest fragment of PEX5L that retains
interaction with PEX7 in the mammalian two-hybrid assay (amino acids
191-222), indicating that it may play an important role in
PEX5L·PEX7 interaction. The fact that this conserved motif is 8 amino
acids longer than the smallest PEX7-interacting fragment and the fact
that a somewhat longer PEX5 fragment PEX5L/191-251 shows an even
stronger interactions may indicate that indeed the region including
amino acids 209-229 of PEX5L is most important for the interaction
with PEX7. This hypothesis is supported by a recent study from the
Fujiki laboratory, which showed that substitution of phenylalanine for
a conserved serine of this motif (Ser-213 of human PEX5)
eliminates PTS2 protein import and disrupts the PEX5L·PEX7
interaction (80). The hypothesis that this 21-amino acid motif may be
important for interaction with PEX7 is also supported by the fact that
this motif is located within regions of Pex18p and Pex21p that are
sufficient for interaction with yeast Pex7p (77).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Alignment of PEX5L with
ScPex18p and ScPex21p reveals a motif
21 amino acids long common to all three proteins. The
underlined sequence indicates the amino acids encoded by the
alternative exon of PEX5L. The asterisk indicates the serine
that is mutated in the PTS2-deficient cell line with a Ser to Phe
mutation in PEX5 (80).
|
|
The possibility that PEX5L may represent a functional homolog of
S. cerevisiae Pex18p and/or Pex21p predicts that PEX5L may interact with S. cerevisiae Pex7p and that S. cerevisiae Pex18p and/or Pex21p may interact with human PEX7.
Using the yeast two-hybrid assay, we observed that human PEX5L did
indeed interact with yeast Pex7p whereas PEX5S did not interact with
yeast Pex7p (Fig. 9). In addition, the
interaction of S. cerevisiae Pex7p was mapped to the same
region of PEX5L, as with human PEX7. Previous studies have reported
that yeast Pex7p interacts with yeast Pex5p in the yeast two-hybrid
assay but that this interaction is detected only in the presence of
yeast Pex14p. Presumably, Pex14p serves as a bridge between Pex5p and
Pex7p, which do not contact each other directly (50). In contrast, the
interaction between human PEX5L and yeast Pex7p is not reduced in the
absence of Pex14p and in fact may even be stronger in the
pex14-deficient two-hybrid reporter strain. We also tested
whether ScPex21p interacted with human PEX7 using the
mammalian two-hybrid system. We again found evidence of interaction
(Table III) indicating that the
interacting regions of both partners may be conserved.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 9.
Interactions of ScPex7p with
human PEX5 can be mapped to the same region as with
HsPEX7 in a yeast two-hybrid assay and are independent
of ScPex14p. The yeast strains PCY2 and
PCY2 pex14 were double-transformed with plasmids encoding
the indicated Gal4-BD (in pPC86) and Gal4AD fusions (in pPC97) and were
investigated for -galactosidase activation with a filter assay after
selection on SD plates lacking leucine and tryptophan (see
"Experimental Procedures"). Only the PEX5L-derived proteins were
able to interact with ScPex7p. This interaction was
independent of yeast Pex14p.
|
|
The fact that the role of PEX5 in PTS2 protein import differs greatly
between mammalian cells and yeast led us to consider the possibility
that additional differences may exist in PTS2 protein import. We
already supposed that PEX5L could transport PEX7 and its cargo to the
peroxisomal membrane. The two candidates for docking this complex to
the peroxisomal membrane are PEX13 and PEX14. Data available so far
suggest differences between the human and yeast system. Previous
studies have established that S. cerevisiae Pex7p and
S. cerevisiae Pex5p both independently interact with
S. cerevisiae Pex13p and Pex14p, respectively. This has been
shown both in vivo and in two-hybrid assays (50). The interaction between human PEX5 and PEX14 has now been shown by several
groups and is easily detectable (48, 52, 66). Performing co-immunoprecipitations from lysates Fujiki and co-workers found evidence for PEX13-PEX5 (66) and PEX14-PEX7 (53, 66) interactions; however, there is no evidence that these interactions are direct and
the interactions could not be detected in other laboratories (48, 52).
Using the human two hybrid-system we could easily detect the
PEX5·PEX14 interaction (52, and this study) and the PEX5L·PEX7
interaction, but we find no indication for a PEX13-PEX5 interaction,
even when we used the SH3 domain of PEX13 (Table IV). In addition, we did not detect an
interaction between PEX13·PEX7 that was sufficiently high above
background (Table IV). The lack of a PEX14-PEX7 interaction has been
reported previously for the human system (52). Together our data
support the idea that PEX14 is probably the main docking partner not
only for the PTS1 receptor complex (48, 66) but also mediates PTS2
import via PEX5L and PEX7 in the human system. The lack of PEX13-PEX7
and PEX14-PEX7 interactions may explain why PEX7 was not localized to
the peroxisomal membrane in PEX5 deficient cells (Fig. 7).
 |
DISCUSSION |
In their initial description of PEX5, McCollum et
al. (25) reported that this peroxin was not required for PTS2
protein import in the yeast Pichia pastoris. The subsequent
observation that PEX5 is essential for PTS2 protein import in human
cells was therefore unexpected (27, 29). However, studies showing that
PEX5 is also essential for PTS2 protein import in hamster cells (65)
and mice (63) have firmly established the central role of PEX5 in PTS2
protein import in mammalian cells. The different roles of PEX5 in PTS2
protein import in fungi and mammals are likely to reveal core
properties of the PTS2 protein import pathway, and this topic has
attracted considerable attention within the field. Mammalian
PEX5 RNAs are alternatively spliced to generate two isoforms
of PEX5, which differ by 37 amino acids. The longer isoform, PEX5L, is
the form that participates in PTS2 protein import (64, 65). Recent
studies from Fujiki and colleagues (48, 66) have furthered our
understanding by establishing that PEX7 displays preferential binding
to PEX5L as compared with PEX5S. In this report we used a combination
of functional complementation assays, mammalian two-hybrid assays, and
protein targeting assays to identify regions of PEX5L that are
sufficient for PTS2 rescue, interaction with PEX7, and targeting to peroxisomes.
PEX5L is a protein 639-amino acids long. Previous studies have
established that amino acids 299-639 are involved in PTS1 recognition (27, 31, 79) and interaction with PEX12 (79) and that amino acids
1-298 are involved in interaction with PEX14 (70, 81). Positive
results in a variety of assays have allowed us to enrich the functional
domain map of PEX5L (Fig. 10) by
showing that amino acids 1-230 are sufficient for rescuing PTS2
protein import in PEX5-deficient human cells, amino acids
191-222 are sufficient for interaction with PEX7, and amino acids
1-214 are sufficient for peroxisomal targeting. These results support
the view of PEX5 as a modular, multidomain protein that interacts with
numerous proteins during the matrix protein import process. Other
protein interaction sites that remain to be mapped in PEX5 include the
binding sites for PEX10 (82), Pex8p (83), and perhaps other
PEX5-binding proteins that remain to be described.

View larger version (6K):
[in this window]
[in a new window]
|
Fig. 10.
Diagram of PEX5 functional domains.
White boxes represent the six TPR domains involved in PTS1
binding. The amino acids encoded by the alternative exon
(AE) are indicated by the gray box.
|
|
Prior studies showing that PEX5L, but not PEX5S, mediated PTS2 protein
import and PEX7 interaction (64-66) suggested that the 37-amino acid
insert of PEX5L played an important role in these processes. However,
several lines of evidence suggest that PEX7 interaction requires
additional sequences N-terminal to the insert and may require only the
N-terminal portion of the insert. We observed that the C-terminal 21 amino acids of the 37-amino acid insert could be removed without
significantly reducing the ability of PEX5L to rescue PTS2 protein
import. We also identified a peptide motif at amino acids 209-229 that
spans the N-terminal boundary of the insert, is shared by the PEX7
binding domains of yeast Pex18p and Pex21p proteins, and lies within
the smallest PTS2 rescue and PEX7 interaction domains we identified in
PEX5L. Matsumura et al. (80) identified a single amino acid
substitution mutation in PEX5 that eliminated only PTS2
protein import and reduced the interaction of PEX5L with PEX7. This
serine to phenylalanine missense mutation alters a serine of the
conserved peptide motif that is located two amino acids N-terminal of
the 37-amino acid insert, lending additional support to the hypothesis
that the PEX7 interaction domain spans the N-terminal boundary of the
insert in PEX5L. Finally, we observed that a fragment of PEX5L lacking
sequences upstream of the 37-amino acid insert failed to interact with
PEX7 in the mammalian two-hybrid assay. Although there is no control
for the folding of this PEX5L fragment, the fragment was properly
expressed and localized and the result is at least consistent with the
hypothesis that PEX7 interaction requires amino acids upstream of the
insert. Additionally, we emphasize that our data do not demonstrate
direct interaction between PEX5L and PEX7. In fact, we would argue that the existing data in the literature also fails to demonstrate direct
PEX5L·PEX7 binding (66). We also note that our negative results are
largely uncontrolled, can be accounted for by experimental artifact,
and should not be interpreted as evidence that the PEX5L·PEX7 interaction is indirect.
Like yeast Pex18p and Pex21p, PEX5L is required for PTS2 protein
import, interacts with PEX7, and is necessary for PEX7 transport to
peroxisomes. In addition to these functional similarities, the presence
of a shared peptide motif in all three proteins shows that they also
share some structural similarities. These common properties suggest
that PEX5L may have acquired one or more of the roles that yeast Pex18p
and Pex21p perform in PTS2 protein import. One possibility is that
PEX5L may have replaced either Pex18p or Pex21p, but such a simple
model ignores the fact that PEX5L is essential for PTS2 protein import,
whereas PTS2 protein import in yeast is blocked only by the loss of
both Pex18p and Pex21p. Therefore, a more likely model would have PEX5L
replacing both Pex18p and Pex21p. Another attractive possibility is
that the role of these PEX7-associated proteins has changed through evolution in such a way that the Pex18p- and Pex21p-like activities would both be essential for PTS2 protein import and PEX7 interaction. The identification of human orthologs of Pex18p and Pex21p would help
distinguish between these various possibilities, and, although we have
been unable to identify Pex18p or Pex21p genes in humans, this failure
hardly represents strong evidence that Pex18p and Pex21p are absent.
A further comparison of all other known PEX5 sequences revealed
that this conserved motif and, therefore, the long form of PEX5
are only found in mammals; plants (18, 84) (Arabidopsis thaliana: AF074843); and protozoa Leishmania donovani
(85) and Trypanosoma brucei (86) but not in
Caenorhabditis elegans (C34C6.6) (87); Drosophila
melanogaster (AAF45676.1); or different yeast species. For all
species that share the common PEX7 binding motif there is evidence for
PEX7 as in A. thaliana (AAF88113), or at least evidence for
proteins with a PTS2 targeting signal as in plants and T. brucei (88). Our results suggest that PTS2 import may be similar
in mammals, plants, and protozoa but different in yeasts. As for
C. elegans, which appears to lack PEX7 (89), PEX5 (87) lacks
the PEX7 interaction motif. In addition, orthologs of mammalian PTS2
proteins in C. elegans lack a PTS2 signal and instead are
imported via a PTS1, indicating that the PTS2 pathway may be absent in
C. elegans (89).
 |
ACKNOWLEDGEMENTS |
We are grateful to Tamie Yahraus, Xian Zhong
Xu, Nancy Braverman, Monika Soukupová, Christiane Sprenger,
Wolfgang Schliebs, and Garnet Will for providing plasmids and Christina
Klein for technical assistance.
 |
FOOTNOTES |
*
This work was supported in part by
Forschungsförderung Ruhr-Universität Bochum
Medìcinische Facultät of the Medizinische Fakultät, Ruhr-Universität Bochum and by the Thyssen
Stiftung.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a Lise Meitner fellowship of the State North
Rhine-Wessphalia. To whom correspondence should be addressed:
Institut für Physiologische Chemie, Systembiochemie,
Ruhr-Universität Bochum, Universitätsstr. 150, Bochum
44801, Germany. Tel.: 49-234-32-24938; Fax: 49-234-32-14279; E-mail:
gabriele.dodt@ruhr-uni-bochum.de.
Published, JBC Papers in Press, September 6, 2001, DOI 10.1074/jbc.M106932200
 |
ABBREVIATIONS |
The abbreviations used are:
PTS, peroxisomal
targeting signal;
TPRs, tetratricopeptide repeats;
AD, activation
domain;
BD, binding domain;
CAT, chloramphenicol acetyltransferase;
EGFP, enhanced green fluorescence protein;
IIP, indirect
immunofluorescence;
IPs, immunoprecipitates;
PBDs, peroxisome
biogenesis disorders;
PCR, polymerase chain reaction;
PAGE, polyacrylamide gel electrophoresis;
PVDF, polyvinylidene difluoride;
ELISA, enzyme-linked immunosorbent assay.
 |
REFERENCES |
| 1.
|
Wanders, R. J.,
and Tager, J. M.
(1998)
Mol. Asp. Med.
19,
69-154
|
| 2.
|
Tolbert, N. E.
(1981)
Annu. Rev. Biochem.
50,
133-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Lazarow, P. B.,
and Fujiki, Y.
(1985)
Ann. Rev. Cell Biol.
1,
489-530[CrossRef]
|
| 4.
|
Subramani, S.
(1993)
Annu. Rev. Cell Biol.
9,
445-478[CrossRef]
|
| 5.
|
Gould, S. J.,
Keller, G. A.,
Hosken, N.,
Wilkinson, J.,
and Subramani, S.
(1989)
J. Cell Biol.
108,
1657-1664[Abstract/Free Full Text]
|
| 6.
|
Purdue, P. E.,
and Lazarow, P. B.
(1996)
J. Cell Biol.
134,
849-862[Abstract/Free Full Text]
|
| 7.
|
Amery, L.,
Brees, C.,
Baes, M.,
Setoyama, C.,
Miura, R.,
Mannaerts, G. P.,
and Van Veldhoven, P. P.
(1998)
Biochem. J.
336,
367-371
|
| 8.
|
Shimozawa, N.,
Zhang, Z.,
Suzuki, Y.,
Imamura, A.,
Tsukamoto, T.,
Osumi, T.,
Fujiki, Y.,
Orii, T.,
Barth, P. G.,
Wanders, R. J.,
and Kondo, N.
(1999)
Biochem. Biophys. Res. Commun.
262,
504-508[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Geisbrecht, B. V.,
Zhang, D.,
Schulz, H.,
and Gould, S. J.
(1999)
J. Biol. Chem.
274,
21797-21803[Abstract/Free Full Text]
|
| 10.
|
Jones, J. M.,
and Gould, S. J.
(2000)
Biochem. Biophys. Res. Commun.
275,
233-240[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Jones, J. M.,
Morrell, J. C.,
and Gould, S. J.
(2000)
J. Biol. Chem.
275,
12590-12597[Abstract/Free Full Text]
|
| 12.
|
Lametschwandtner, G.,
Brocard, C.,
Fransen, M.,
Van Veldhoven, P.,
Berger, J.,
and Hartig, A.
(1998)
J. Biol. Chem.
50,
33635-33643
|
| 13.
|
Hansen, H.,
Didion, T.,
Thiemann, A.,
Veenhuis, M.,
and Roggenkamp, R.
(1992)
Mol. Gen. Genet.
235,
269-278[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
De Hoop, M. J.,
and Ab, G.
(1992)
Biochem. J.
286,
657-669
|
| 15.
|
Fung, K.,
and Clayton, C.
(1991)
Mol. Biochem. Parasitol.
45,
261-264[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Keller, G. A.,
Krisans, S.,
Gould, S. J.,
Sommer, J. M.,
Wang, C. C.,
Schliebs, W.,
Kunau, W.,
Brody, S.,
and Subramani, S.
(1991)
J. Cell Biol.
114,
893-904[Abstract/Free Full Text]
|
| 17.
|
Sommer, J. M.,
Cheng, Q. L.,
Keller, G. A.,
and Wang, C. C.
(1992)
Mol. Biol. Cell
3,
749-759[Abstract]
|
| 18.
|
Kragler, F.,
Lametschwandtner, G.,
Christmann, J.,
Hartig, A.,
and Harada, J. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13336-13341[Abstract/Free Full Text]
|
| 19.
|
Swinkels, B. W.,
Gould, S. J.,
Bodnar, A. G.,
Rachubinski, R. A.,
and Subramani, S.
(1991)
EMBO J.
10,
3255-3262[Medline]
[Order article via Infotrieve]
|
| 20.
|
Osumi, T.,
Tsukamoto, T.,
Hata, S.,
Yokota, S.,
Miura, S.,
Fujiki, Y.,
Hijikata, M.,
Miyazawa, S.,
and Hashimoto, T.
(1991)
Biochem. Biophys. Res. Commun.
181,
947-954[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Glover, J. R.,
Andrews, D. W.,
Subramani, S.,
and Rachubinski, R. A.
(1994)
J. Biol. Chem.
269,
7558-7563[Abstract/Free Full Text]
|
| 22.
|
Gietl, C.,
Faber, K. N.,
van der Klei, I. J.,
and Veenhuis, M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3151-3155 |